Salarius Pharmaceuticals, Inc.

About Salarius Pharmaceuticals, Inc.

Salarius is a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients in need of new treatment options. Their technologies aim to correct dysregulated gene expression in cancer cells, addressing the root causes of cancer development and progression.

Products & Services

Targeted Protein Inhibition (TPI):A class of drugs, including seclidemstat (SP-2577), currently in phase 1/2 trials, designed to inhibit proteins that dysregulate gene expression in cancer cells.

Specialties

Cancer treatment Targeted protein inhibition Targeted protein degradation Gene expression regulation Solid and hematologic cancers

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2023-05-16 FD: 2023-05-16	-
2	RT: Private Placement T: - FT: Private Placement	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2023-05-12 FD: 2023-05-12	1 investors
3	RT: Grant T: - FT: Grant	A: 1480000 MR: - FA: $1.48 million FAN: 1480000	D: 2023-02-16 FD: 2023-02-16	1 investors

Private Placement Latest

2023-05-16

$6.0M

Private Placement 2023-05-12

$6.0M

Grant 2023-02-16

$1.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David J. Arthur

Chief Executive Officer

M

Mark J. Rosenblum

Chief Financial Officer

N

Nadeem Q. Mirza

Senior Vice President, Clinical Development

R

Rebecca Griffith-Eskew

Vice President, Clinical Operations

W

William McVicar

CHAIRMAN, BOARD OF DIRECTORS

J

Jonathan Lieber

Managing Director of Danforth Advisors and Consulting Chief Financial Officer

View 7 more team members with Pro

Unlock Full Team Directory

Recent News